Skip to main content
Log in

Gastro-Oesophageal Reflux Disease

Beyond Proton Pump Inhibitor Therapy

  • Current Opinion
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Gastro-oesophageal reflux disease (GORD or GERD) is a very common disorder, and advancement in drug development over the years has markedly improved disease management. Proton pump inhibitors (PPIs) remain the mainstay of treatment for GERD due to their profound and consistent inhibitory effect on acid secretion. However, PPIs do not reduce the number of reflux events and do not provide long-term cure for GERD. In addition, although the safety profile of PPIs is excellent, recent population-based studies have suggested that long-term PPI use may be associated with a variety of adverse events. They include osteoporosis-related hip and spine fractures, community-acquired and nosocomial pneumonia, various enteric and non-enteric infections, fundic gland polyps and many others. Consequently, there is growing interest by patients and physicians alike in current, as well as future, non-PPI-related therapeutic strategies for GERD. This includes repositioning histamine H2 receptor antagonists and prokinetics in our current GERD therapeutic algorithms and a resurgence of non-medical therapeutic modalities for GERD, such as anti-reflux surgery, endoscopic treatment, alternative and complementary medicine and psychological interventions. Furthermore, there will be renewed efforts in further developing new medical and non-medical therapeutic modalities for GERD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II

Similar content being viewed by others

References

  1. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 May; 54(5): 710–7

    Article  PubMed  CAS  Google Scholar 

  2. Locke 3rd GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997 May; 112(5): 1448–56

    Article  PubMed  Google Scholar 

  3. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976 Nov; 21(11): 953–6

    Article  PubMed  CAS  Google Scholar 

  4. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology 2002 May; 122(5): 1500–11

    Article  PubMed  Google Scholar 

  5. Chiba N, De Gara CJ, Wilkinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997 Jun; 112(6): 1798–810

    Article  PubMed  CAS  Google Scholar 

  6. Fass R, Shapiro M, Dekel R, et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease. Where next? Aliment Pharmacol Ther 2005 Jul 15; 22(2): 79–94

    Article  CAS  Google Scholar 

  7. Moore JM, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease: real or imagined? Curr Opin Gastroenterol 2010 Jul; 26(4): 389–94

    Article  PubMed  Google Scholar 

  8. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004 Oct 27; 292(16): 1955–60

    Article  PubMed  CAS  Google Scholar 

  9. Dial S, Alrasadi K, Manoukian C, et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004 Jul 6; 171(1): 33–8

    Article  PubMed  Google Scholar 

  10. Keszthelyi D, Jansen SV, Schouten GA, et al. Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study. Aliment Pharmacol Ther 2010 Nov; 32(9): 1124–8

    Article  PubMed  CAS  Google Scholar 

  11. Lombardo L, Foti M, Ruggia O, et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol 2010 Jun; 8(6): 504–8

    Article  PubMed  Google Scholar 

  12. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology 2010 Oct; 139(4): 1115–27

    Article  PubMed  CAS  Google Scholar 

  13. McColl KE. Effect of proton pump inhibitors on vitamins and iron. Am J Gastroenterol 2009 Mar; 104 Suppl. 2: S5–9

    Article  PubMed  CAS  Google Scholar 

  14. Furlanetto TW, Faulhaber GA. Hypomagnesemia and proton pump inhibitors: below the tip of the iceberg. Arch Intern Med 2011 Aug 8; 171(15): 1391–2

    Article  PubMed  Google Scholar 

  15. Reimer C, Sondergaard B, Hilsted L, et al. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology 2009 Jul; 137(1): 80–7

    Article  PubMed  CAS  Google Scholar 

  16. Niklasson A, Lindstrom L, Simren M, et al. Dyspeptic symptom development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial. Am J Gastroenterol 2010 Jul; 105(7): 1531–7

    Article  PubMed  CAS  Google Scholar 

  17. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010 Jan; 105(1): 34–41

    Article  PubMed  CAS  Google Scholar 

  18. Fass R, Hixson LJ, Ciccolo ML, et al. Contemporary medical therapy for gastroesophageal reflux disease. Am Fam Physician 1997 Jan; 55(1): 205–12, 17–8

    PubMed  CAS  Google Scholar 

  19. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology2000 Feb; 118 (2 Suppl. 1): S9–31

    Article  PubMed  CAS  Google Scholar 

  20. Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005 Jul 14; 11(26): 4067–77

    PubMed  CAS  Google Scholar 

  21. Johnson NJ, Boyd EJ, Mills JG, et al. Acute treatment of reflux oesophagitis: a multicentre trial to compare 150 mg ranitidine b.d. with 300mg ranitidine q.d.s. Aliment Pharmacol Ther 1989 Jun; 3(3): 259–66

    Article  PubMed  CAS  Google Scholar 

  22. Kahrilas PJ, Fennerty MB, Joelsson B. High-versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999 Jan; 94(1): 92–7

    Article  PubMed  CAS  Google Scholar 

  23. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998; 115(6): 1335–9

    Article  PubMed  CAS  Google Scholar 

  24. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002; 122(3): 625–32

    Article  PubMed  CAS  Google Scholar 

  25. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007 Dec; 5(12): 1385–91

    Article  PubMed  CAS  Google Scholar 

  26. Zhang Q, Lehmann A, Ridga R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002; 50(1): 19–24

    Article  PubMed  CAS  Google Scholar 

  27. Koek GH, Sifrim D, Lerut T, et al. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 2003 Oct; 52(10): 1397–402

    Article  PubMed  CAS  Google Scholar 

  28. Vela MF, Tutuian R, Katz PO, et al. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003 Jan; 17(2): 243–51

    Article  PubMed  CAS  Google Scholar 

  29. Gerson LB, Huff FJ, Hila A, et al. Arbaclofen placarbil decreases postprandial reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 2010 Jun; 105(6): 1266–75

    Article  PubMed  CAS  Google Scholar 

  30. Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010 Aug; 139(2): 409–17

    Article  PubMed  CAS  Google Scholar 

  31. Boeckxstaens GE, Beaumont H, Hatlebakk JG, et al. Efficacy and tolerability of the novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy [abstract]. Gastroenterology 2009 May; 136 (5 Suppl. 1): A–436

    Google Scholar 

  32. Frisby CL, Mattsson JP, Jensen JM, et al. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 2005 Sep; 129(3): 995–1004

    Article  PubMed  CAS  Google Scholar 

  33. Keywood C, Wakefield M, Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009 Sep; 58(9): 1192–9

    Article  PubMed  CAS  Google Scholar 

  34. Partosoedarso ER, Abrahams TP, Scullion RT, et al. Cannabinoid 1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 2003 Jul 1; 550 (Pt 1): 149–58

    Article  PubMed  CAS  Google Scholar 

  35. Beaumont H, Jensen J, Carlsson A, et al. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 2009 Jan; 156(1): 153–62

    Article  PubMed  CAS  Google Scholar 

  36. Scarpellini E, Blondeau K, Boecxstaens V, et al. Effect of rimonabant on oesophageal motor function in man. Aliment Pharmacol Ther 2011 Mar; 33(6): 730–7

    Article  PubMed  CAS  Google Scholar 

  37. Hershcovici T, Fass R. Transient lower oesophageal sphincter relaxation reducers: have we hit a brick wall? Aliment Pharmacol Ther 2011 Jun; 33(11): 1256–7; author reply 7-8

    Article  PubMed  CAS  Google Scholar 

  38. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American gastroenterological association medical position statement on the management of gastroesophageal reflux disease. Gastroenterology 2008 Oct; 135(4): 1383–91

    Article  PubMed  Google Scholar 

  39. Masci E, Testoni PA, Passaretti S, et al. Comparison of ranitidine, domperidone maleate and ranitidine+domperidone maleate in the short-term treatment of reflux oesophagitis. Drugs Exp Clin Res 1985; 11(10): 687–92

    PubMed  CAS  Google Scholar 

  40. Kim YS, Kim TH, Choi CS, et al. Effect of itopride, a new prokinetic, in patients with mild GERD: a pilot study. World J Gastroenterol 2005 Jul 21; 11(27): 4210–4

    PubMed  CAS  Google Scholar 

  41. Scarpellini E, Vos R, Blondeau K, et al. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther 2011 Jan; 33(1): 99–105

    Article  PubMed  CAS  Google Scholar 

  42. Ruth M, Hamelin B, Rohss K, et al. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998 Jan; 12(1): 35–40

    Article  PubMed  CAS  Google Scholar 

  43. Cho YK, Choi MG, Han HW, et al. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. J Clin Gastroenterol 2006 Apr; 40(4): 286–92

    Article  PubMed  CAS  Google Scholar 

  44. Boulant J, Fioramonti J, Dapoigny M, et al. Cholecystokinin and nitric oxide in transient lower esophageal sphincter relaxation to gastric distention in dogs. Gastroenterology 1994 Oct; 107(4): 1059–66

    PubMed  CAS  Google Scholar 

  45. Zerbib F, Bruley Des Varannes S, Scarpignato C, et al. Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. Am J Physiol 1998 Dec; 275 (6 Pt 1): G1266–73

    PubMed  CAS  Google Scholar 

  46. Choung RS, Ferguson DD, Murray JA, et al. A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double-blind, placebocontrolled pharmacodynamic study. Aliment Pharmacol Ther 2008 Mar 1; 27(5): 404–11

    Article  PubMed  CAS  Google Scholar 

  47. Krarup AL, Ny L, Astrand M, et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther 2011 May; 33(10): 1113–22

    Article  PubMed  CAS  Google Scholar 

  48. del Genio G, Tolone S, del Genio F, et al. Total fundoplication controls acid and nonacid reflux: evaluation by pre- and postoperative 24-h pH-multichannel intraluminal impedance. Surg Endosc 2008 Nov; 22(11): 2518–23

    Article  PubMed  Google Scholar 

  49. Kahrilas PJ. Surgical therapy for reflux disease. JAMA 2001 May 9; 285(18): 2376–8

    Article  PubMed  CAS  Google Scholar 

  50. Galmiche JP, Hatlebakk J, Attwood S, et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011 May 18; 305(19): 1969–77

    Article  PubMed  CAS  Google Scholar 

  51. Schwartz MP, Smout AJ. Review article: the endoscopic treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007 Dec; 26 Suppl. 2: 1–6

    Article  PubMed  Google Scholar 

  52. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001 May 9; 285(18): 2331–8

    Article  PubMed  CAS  Google Scholar 

  53. Louis H, Deviere J. Ensocopic-endoluminal therapies: a critical appraisal. Best Pract Res Clin Gastroenterol 2010 Dec; 24(6): 969–79

    Article  PubMed  Google Scholar 

  54. Cadiere GB, Buset M, Muls V, et al. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg 2008 Aug; 32(8): 1676–88

    Article  PubMed  Google Scholar 

  55. Hoppo T, Immanuel A, Schuchert M, et al. Transoral incisionless fundoplication 2.0 procedure using EsophyX for gastroesophageal reflux disease. J Gastrointest Surg 2010 Dec; 14(12): 1895–901

    Article  PubMed  Google Scholar 

  56. Kim MS, Holloway RH, Dent J, et al. Radiofrequency energy delivery to the gastric cardia inhibits triggering of transient lower esophageal sphincter relaxation and gastroesophageal reflux in dogs. Gastrointest Endosc 2003 Jan; 57(1): 17–22

    Article  PubMed  Google Scholar 

  57. Arts J, Sifrim D, Rutgeerts P, et al. Influence of radio-frequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig Dis Sci 2007 Sep; 52(9): 2170–7

    Article  PubMed  CAS  Google Scholar 

  58. Corley DA, Katz P, Wo JM, et al. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003 Sep; 125(3): 668–76

    Article  PubMed  Google Scholar 

  59. Bonavina L, Saino GI, Bona D, et al. Magnetic augmentation of the lower esophageal sphincter: results of a feasibility clinical trial. J Gastrointest Surg 2008 Dec; 12(12): 2133–40

    Article  PubMed  Google Scholar 

  60. Bonavina L, DeMeester T, Fockens P, et al. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one- and 2-year results of a feasibility trial. Ann Surg 2010 Nov; 252(5): 857–62

    Article  PubMed  Google Scholar 

  61. Zou D, Chen WH, Iwakiri K, et al. Inhibition of transient lower esophageal sphincter relaxations by electrical acupoint stimulation. Am J Physiol Gastrointest Liver Physiol 2005 Aug; 289(2): G197–201

    Article  PubMed  CAS  Google Scholar 

  62. Dickman R, Schiff E, Holland A, et al. Clinical trial: acupuncture vs. doubling the proton pump inhibitor dose in refractory heartburn. Aliment Pharmacol Ther 2007 Nov 15; 26(10): 1333–44

    CAS  Google Scholar 

  63. Nojkov B, Rubenstein JH, Adlis SA, et al. The influence of co-morbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2008; 27(6): 473–82

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

Dr Fass has received research support from AstraZeneca and Reckitt-Benckiser and served as a speaker for Takeda, and as a consultant for Shire, Takeda, Vecta and Reckitt-Benckiser. Dr Hershcovici has no conflicts of interest that are directly relevant to the content of this article. No sources of funding were used in the preparation of this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ronnie Fass MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hershcovici, T., Fass, R. Gastro-Oesophageal Reflux Disease. Drugs 71, 2381–2389 (2011). https://doi.org/10.2165/11597300-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11597300-000000000-00000

Keywords

Navigation